Table 2:
Characterization and validation
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography | All lines exhibit normal morphology | Figure 1A, Supplementary Figure 1A |
| Phenotype | Qualitative analysis | All lines exhibit expression of self-renewal markers NANOG, OCT3/4, & SOX2 | Figure 1A, Supplementary Figure 1A |
| Quantitative analysis | All lines were greater than 90% positive for OCT4, SOX2 and NANOG | Figure 1B, Supplementary Figure 1B | |
| Genotype | G-banding Karyotype | 46,XX or 46,XY Normal Karyotype, resolution 425–600 nm | Figure 1A, Supplementary Figure 1A |
| Identity | STR analysis | STR analysis defines profile for each line, confirms clonality and purity to 95–98% confidence | Available with authors |
| 15 loci tested, all matched appropriate source fibroblasts | |||
| Mutation analysis (IF APPLICABLE) | Sequencing | Not Applicable | Not Applicable |
| Southern Blot OR WGS | Not Applicable | Not Applicable | |
| Microbiology and virology | Mycoplasma | Negative | Supplementary Figure 2 |
| Differentiation potential | Directed differentiation | Trilineage differentiation (StemCell Technologies) and qPCR verification, all lines express markers of each germ layer | Figure 1D, Supplementary Figure 1C |
| Donor screening (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A | N/A |
| Genotype additional info (OPTIONAL) | Blood group genotyping | N/A | N/A |
| HLA tissue typing | N/A | N/A |